SCHEMBL22453418

SCHEMBL22453418

COC(=O)c1ccccc1Nc1ccc(N(C)c2ccc(C34CC5CC(CC(C5)C3)C4)cc2)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TAS2R14 Q9NYV8 3/20 0.41
▸ SMO Q99835 5/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ RCE1 Q9Y256 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MDH1 P40925 1/20 0.38
▸ MDH2 P40926 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ HIF1A Q16665 3/20 0.37
▸ EPAS1 Q99814 2/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ GPR55 Q9Y2T6 1/20 0.36
▸ RBP4 P02753 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22453410 0.87 CNR2 (0.46) SMOLMNAMAPTMDH1MDH2
SCHEMBL22452675 0.87 MDH1 (0.39) EPHX2LMNAHTTNPSR1RCE1
SCHEMBL22452674 0.81 CNR2 (0.42) LMNAHTTNPSR1RCE1MAPT
SCHEMBL22452612 0.79 MAPT (0.46) TAS2R14EPHX2LMNAMAPTALOX15
SCHEMBL22452503 0.79 MAPT (0.58) EPHX2LMNAHTTNPSR1RCE1
SCHEMBL22452501 0.79 MAPT (0.55) EPHX2NPSR1MAPTALOX15MDH1
SCHEMBL22453252 0.78 HIF1A (0.39) EPHX2LMNAHTTNPSR1RCE1
SCHEMBL22453203 0.77 CNR2 (0.54) EPHX2LMNAHTTNPSR1RCE1
SCHEMBL22452810 0.76 HIF1A (0.53) TAS2R14EPHX2LMNAHTTNPSR1
SCHEMBL22452652 0.76 EPHX2 (0.61) EPHX2LMNAMAPTALOX15MDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020190774-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS THE GENERAL HOSPITAL CORPORATION (US) 2020-09-24 — — WO disclosed
Send feedback